Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toremifene for bone fracture risk in prostate cancer patients on ADT
NCT01214291Phase 3Withdrawn
- Sponsor
- GTx
- Start
- Mar 2011
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bone fracture (Fx) comparing Toremifene Arm with Placebo Arm (2 arms). Primary endpoint: Incidence of new vertebral fractures at 36 months. Planned start Mar 2011; status: withdrawn.
02
Drugs
toremifene
03
Conditions
bone fracture (Fx)
Beyond the preview
Go deeper on NCT01214291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214291.